Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Jacobson Pharma's share price for the quarter that ended in Mar. 2026 was HK$1.23. Jacobson Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2,000 Mil. Therefore, Jacobson Pharma's market cap for the quarter that ended in Mar. 2026 was HK$2,460 Mil.
Jacobson Pharma's quarterly market cap
increased
from Mar. 2025 (HK$2,353 Mil) to Sep. 2025 (HK$2,920 Mil) but then
declined
from Sep. 2025 (HK$2,920 Mil) to Mar. 2026 (HK$2,460 Mil).
Jacobson Pharma's annual market cap
increased
from Mar. 2024 (HK$1,168 Mil) to Mar. 2025 (HK$2,353 Mil) and
increased
from Mar. 2025 (HK$2,353 Mil) to Mar. 2026 (HK$2,460 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Jacobson Pharma's Enterprise Value for Today is HK$2,655 Mil.
Jacobson Pharma (HKSE:02633) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Jacobson Pharma Market Cap Related Terms
Jacobson Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Jacobson Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a Market Cap of HK$2,070 Mil as of Sep. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Jacobson Pharma and its competitors. According to the industry distribution chart, Jacobson Pharma ranks #497 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 48.6%.
Is Jacobson Pharma's Market Cap too high?
Jacobson Pharma's current Market Cap is HK$2,070 Mil. Based on the distribution chart, Jacobson Pharma ranks #497 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #497 out of 1023 companies for Market Cap. This puts Jacobson Pharma in the upper half of its industry. The industry median Market Cap is 234.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 234.62, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 234.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current Market Cap is HK$2,070 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Market Cap is HK$2,070 Mil. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Market Cap is HK$2,070 Mil as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
Market Cap: HK$2,070 Mil
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
